Pathophysiology of tumor neovascularization.
Pathophysiology of tumor neovascularization.
复制标题
DOI：
10.2147/vhrm.2005.1.4.277
复制
发表时间：
2005
影响因子：
2.9
通讯作者：
Ishikura H
中科院分区：
文献类型：
--
作者：
Furuya M;Nishiyama M;Kasuya Y;Kimura S;Ishikura H
新生血管在脊椎动物胚胎组织的发育和分化过程中是必不可少的，也参与了成年动物的各种生理和病理状况，包括伤口修复、代谢性疾病、炎症、心血管疾病和肿瘤进展。由于对血管系统的累积研究，通过控制受影响器官中的血管生成，为我们打开了一些威胁生命的疾病的新的治疗方法。例如，在癌症治疗中，调节负责肿瘤血管生成的因子可能有助于抑制肿瘤的进展。几种抗血管生成的方法目前正在进行临床前试验。然而，肿瘤新生血管形成的机制是复杂的，每个肿瘤的血管系统都有其独特的特点，这取决于组织的特异性、血管生成的微环境、分级和分期、宿主免疫等。为了更好地理解和有效的治疗方法，阐明血管生成事件的一般机制和新生血管的疾病特异性机制是很重要的。这篇综述讨论了生理和病理条件下血管生成的一般特征，主要是在肿瘤进展过程中。此外，还对血管内皮祖细胞的作用、肿瘤血管生成拟态、肿瘤来源的内皮细胞和周细胞的标记物以及血管生成/抑血管趋化因子等方面的研究进展进行了综述。
Neovascularization is essential to the process of development and differentiation of tissues in the vertebrate embryo, and is also involved in a wide variety of physiological and pathological conditions in adults, including wound repair, metabolic diseases, inflammation, cardiovascular disorders, and tumor progression. Thanks to cumulative studies on vasculature, new therapeutic approaches have been opened for us to some life-threatening diseases by controlling angiogenesis in the affected organs. In cancer therapy, for example, modulation of factors responsible for tumor angiogenesis may be beneficial in inhibiting of tumor progression. Several antiangiogenic approaches are currently under preclinical trial. However, the mechanisms of neovascularization in tumors are complicated and each tumor shows unique features in its vasculature, depending on tissue specificity, angiogenic micromilieu, grades and stages, host immunity, and so on. For better understanding and effective therapeutic approaches, it is important to clarify both the general mechanism of angiogenic events and the disease-specific mechanism of neovascularization. This review discusses the general features of angiogenesis under physiological and pathological conditions, mainly in tumor progression. In addition, recent topics such as contribution of the endothelial progenitor cells, tumor vasculogenic mimicry, markers for tumor-derived endothelial cells and pericytes, and angiogenic/angiostatic chemokines are summarized.